Innovation for Health - 13 February 2020
Contact Investor Forum I4H Bootcamp
LinkedIn
Twitter
Facebook
Innovation for Health - Shaping the future of healthcare

Asiya Giniatullina

Forbion

Senior Associate, Forbion 
Asiya is Senior Associate and joined the Forbion team in 2018.
Between 2013 and 2018, Asiya has worked at bluebird bio in Cambridge MA in Business Development, Alliance Management and Research Strategy roles. At bluebird, Asiya has contributed to expanding the company pipeline by helping identify and evaluate early-stage technologies (e.g. gene editing, resulting in the acquisition of gene editing company Pregenen) and new disease indications. She has been involved in executing and managing several collaborative projects in gene therapy. Most recently, she has led the planning and execution of a program for a new gene therapy product candidate, from ideation through proof-of-concept study, and mapping out the development plan.
Asiya holds a Ph.D. in Neuroscience from the VU University Amsterdam, M.S. in Medical Biotechnology and B.S. in Biotechnology from the University of Trieste, Italy.

About Forbion
Forbion currently manages over €1 bn across ten closed-end funds, including its $360m Forbion IV Fund, launched in 2018, for which Forbion is actively looking for new exciting opportunities. Forbion has a team of thirteen investment professionals across two offices in The Netherlands and Germany. Forbion’s portfolio companies are developing novel drugs, medical devices and diagnostics for high and unmet medical needs. Besides financial support, Forbion helps companies to bridge research and development through the team’s expertise in drug development and company building.

The current portfolio comprises around 27 active investments in companies working in the fields of cancer, kidney disease, liver disease, dyslipidemia, inflammatory bowel disease, anti-infectives, central nervous system pain management, and the microbiome. Recent examples of successful exits include Dezima sold to Amgen for up to $1.55bn and the sale of Acerta Pharma to Astra Zeneca for a total exit value of $7bn (investment by Forbion’s affiliate BioGeneration Ventures)

Sponsors & Partners 2020
Host sponsor
Erasmus MC
Host sponsor
Gemeente Rotterdam
Host sponsor
Life Sciences & Health 010
Gold sponsor
Award sponsor
AXON Lawyers
You?
Become a Sponsor!
Powered by
Hyphen Projects
© 2019 Innovation for Health
Hyphen Projects uses cookies to remember certain preferences.